
SCIENTIFIC DIGITAL JOURNAL

FRONTIERS OF BIOSCIENCE

ISSN # 3085-9069 Dec, 2025 ISSUE N. 19



MAMPs: the invisible language between microorganisms and the immune system

Scientific Digital Journal
frontiersofbioscience@gon1.com.br

https://doi.org/10.6084/m9.figshare.31453786

GUIMARÃES, D.O.
DE ALMEIDA, T.R.G.
DE PROENÇA, L.V.S.

The silent crisis of modern immunity

The twentieth century was marked by unequivocal victories of medicine against devastating infectious diseases. Antibiotics, vaccines and sanitary improvements radically changed global life expectancy. However, as we move into the twenty first century, it became evident that the pattern of global morbidity has changed drastically. Acute infectious diseases have largely given way to chronic inflammatory, metabolic, autoimmune and neurodegenerative diseases.

According to global estimates widely disseminated by international organizations, chronic non communicable diseases account for the majority share of deaths worldwide. Within this group, a substantial fraction shares a common denominator: persistent inflammation, discreet, yet biologically relevant. Metabolic syndrome, type two diabetes, cardiovascular disease, inflammatory bowel diseases, rheumatoid arthritis, multiple sclerosis, major depression with inflammatory subphenotypes and certain neurodegenerative conditions present, at different intensities, a state of chronic low grade inflammation.

This state rarely behaves like a classic acute infection. It looks more like an innate immune system slightly accelerated for too long, like an engine idling that never shuts off. A troubling and central question then arises: what sustains this continuous activation, even when there is no evident pathogen

For many years, the answer was attributed, in a simplified way, to diet, physical inactivity and genetic predisposition. These factors are relevant, but today it is increasingly clear that there is an additional fundamental actor in this scenario: the human microbiota and, above all, the molecular signals it emits and that the host interprets.

The immune system does not react only to invading microorganisms. It reacts to conserved, repetitive, predictable structural patterns present in microorganisms. These patterns are recognized by pattern recognition receptors, PRRs. The modern idea, introduced with clarity by Janeway and deepened by Medzhitov, was that innate immunity needs a fast and efficient detection system to "read" the microbial world, and this reading occurs through patterns, not through individualized identification of species, as discussed by Janeway and Medzhitov in synthesis works in the early 2000s.

In ancestral environments, constant and diverse exposure to microorganisms promoted continuous immunological training, with fine calibration between defense and tolerance. Urbanization, reduced environmental biodiversity, widespread antibiotic use and profound dietary changes reduced this microbial diversity. The result resembles a communication system that lost part of its original vocabulary, and started to respond with noise when it should respond with precision.

The hygiene hypothesis, formulated by Strachan in 1989, was one of the initial milestones when observing an association between family size and hay fever prevalence, suggesting that lower early microbial exposure could favor allergic disease. Since then, the debate has evolved toward more complex models that include biodiversity, immune maturation and dysregulated microbial signaling, with modern reviews discussing how the hypothesis matured and was refined over the decades.

The central point is that the issue is not only having fewer microorganisms, it is having an altered profile of microbial signals. In other words, the quality of the molecular dialogue between the microbiota and the immune system may be compromised.

A didactic and clinically relevant example is metabolic endotoxemia. Cani and collaborators, in 2007, demonstrated in an experimental model that discreetly elevated levels of lipopolysaccharide, associated with diet, can alter inflammatory tone and contribute to

insulin resistance and weight gain. This work helped consolidate the notion that metabolic inflammation can be initiated or amplified by microbial signals, not only by expansion of adipose tissue.
This understanding shifts the paradigm. If part of modern diseases is associated with inadequate signaling of microbial patterns, then rational modulation of these signals can become a promising therapeutic strategy, provided it is approached with rigor, adequate biomarkers and clear limits between association and causality.

But before discussing applications, it is essential to understand what these patterns are and how they interact with the immune system.

MAMPs, definition, classification and structural foundations

MAMPs, Microbe Associated Molecular Patterns, are highly conserved molecular structures present in microorganisms. Unlike specific toxins or virulence factors, MAMPs are structural components essential to microbial survival. Precisely because they are essential, they are evolutionarily stable and predictable, making them ideal targets for immunological recognition.
Among the main bacterial MAMPs, lipopolysaccharides from gram negative bacteria, peptidoglycans of the bacterial wall, lipoteichoic acids of gram positive bacteria, flagellin, and microbial nucleic acids in contexts of endosomal recognition stand out. In fungi, beta glucans and mannans of the cell wall are relevant examples. For viruses, the conceptual tradition still uses PAMPs more frequently, but the reasoning of recognition by patterns remains the same.
Recognition of MAMPs is performed by PRRs, Pattern Recognition Receptors. Among the main PRRs are Toll type receptors, NOD type receptors and cytosolic receptors associated with viral RNA, among others. The work of Akira and collaborators consolidated the view that Toll type receptors are central to initiating inflammation, interferons and calibration of the adaptive response, and comprehensive reviews by Takeuchi and Akira reinforced how PRRs also govern inflammation and homeostasis.


Toll type receptors have classic specificities: TLR4 recognizes lipopolysaccharide with the aid of co receptors and carrier proteins, TLR2 recognizes bacterial lipoproteins and wall components associated with gram positive bacteria, TLR5 recognizes flagellin, and TLR9 recognizes CpG rich DNA in endosomal compartments. A mechanistic detail that improves clinical precision is that TLR4 can signal through MyD88 dependent and TRIF dependent pathways, while TLR2 is predominantly MyD88 dependent.


However, the interaction is not binary. It is not only about turning on or turning off. Intensity, duration, dose, location, cell type and basal inflammatory context determine the outcome. Small structural variations in the lipid A of lipopolysaccharide can profoundly change the activation profile of TLR4, with more strongly agonistic forms associated with more robust inflammatory responses and other variants being able to act as partial agonists.

Moreover, different cell types respond differently to the same pattern. Macrophages, dendritic cells, intestinal epithelial cells and B lymphocytes have different repertoires and thresholds, resulting in distinct cytokine and co stimulation profiles.

This triad (molecular structure of the MAMP, exposed cell type, and physiological context of the host) determines the immune outcome and guides the interpretation of the findings discussed in the following sections.

Recognition of MAMPs by PRRs in the Intestinal Mucosa





The image illustrates how the innate immune system recognizes conserved molecular patterns from microorganisms, known as MAMPs, both at the cell surface and within intracellular compartments. This recognition organizes a coordinated response that may result in inflammation, tolerance, or homeostasis.

The setting depicted is the intestinal mucosa, composed of the intestinal lumen, mucus layer, epithelial barrier, and lamina propria, where immune cells such as macrophages and dendritic cells reside. Recognition does not occur only during active infection, but continuously as part of physiological immune surveillance.

Step 1

Presence of MAMPs in the intestinal lumen

Within the lumen, multiple microbial components are present:

• Lipopolysaccharide, LPS, typical of gram negative bacteria
• Bacterial lipoproteins
• Peptidoglycan from bacterial cell walls
• Lipoteichoic acids from gram positive bacteria
• Flagellin from motile bacteria
• Zymosan and other fungal components
• Bacterial CpG rich DNA

These components are structurally conserved, allowing the immune system to recognize them as predictable molecular patterns.

Step 2

Contact with the epithelial barrier

These MAMPs may:

- Interact directly with receptors on epithelial cell surfaces
- Be captured by dendritic cells extending processes between epithelial cells
- Be internalized by macrophages
- Be endocytosed and directed into endosomal compartments

The intestinal barrier functions as a dynamic filter. Under physiological conditions, this interaction contributes to immune homeostasis. In states of increased permeability, greater translocation of molecular patterns may occur.

Step 3

Recognition by surface and endosomal PRRs

The image shows two major groups of receptors.

1. Plasma membrane receptors

These receptors recognize external microbial structures:

- TLR4, associated with LPS recognition, with the assistance of CD14 and MD 2
- TLR2, which frequently forms heterodimers with TLR1 or TLR6 to recognize lipoproteins and lipopeptides
- TLR5, which recognizes flagellin
- Receptors recognizing fungal components such as zymosan
- These receptors mainly detect structural elements of microbial cell walls or surface appendages.

2. Endosomal receptors

After internalization of microbial material, other TLRs recognize nucleic acids:

• TLR3, which recognizes double stranded viral RNA
• TLR7 and TLR8, which recognize single stranded viral RNA
• TLR9, which recognizes CpG rich bacterial DNA

Endosomal localization is essential to avoid inappropriate recognition of host nucleic acids.

Step 4

Cytosolic NOD family receptors

The image also highlights NOD1 and NOD2, located in the cytosol.

• NOD1 recognizes peptidoglycan fragments containing diaminopimelate motifs, more commonly associated with gram negative bacteria
• NOD2 recognizes muramyl dipeptide, a minimal conserved motif of bacterial peptidoglycan

• NOD1 and NOD2 function as intracellular sensors that complement TLR mediated recognition.

Step 5

Adaptor proteins and signaling bifurcation

Following recognition, TLRs recruit adaptor proteins.

• Most surface TLRs signal primarily through MyD88
• TLR4 can signal through both MyD88 and TRIF
• TLR3 signals predominantly through TRIF
• NOD1 and NOD2 activate signaling pathways involving RIP2

This bifurcation determines intensity, timing, and qualitative profile of the immune response.

Step 6

Activation of transcription factors

Signaling pathways converge on transcription factors, mainly:

• NF kappa B
• Interferon regulatory factors, IRFs

These factors translocate to the nucleus and induce gene expression.

Step 7

Mediator production

Depending on the molecular pattern and physiological context, the response may include:

• Pro inflammatory cytokines such as TNF alpha, IL 1 beta, and IL 6
• Interferons, particularly in viral RNA recognition
• Regulatory cytokines such as IL 10 and TGF beta
• Chemokines
• Antimicrobial peptides

The response is not automatically inflammatory. It depends on dose, frequency, and the host's baseline immune state.

Step 8

Local and systemic outcomes

Locally, the effects may include:

• Modulation of intestinal permeability
• Increased mucus production
• Induction of antimicrobial peptides
• Differentiation of regulatory or effector T cell responses

Systemically, when there is increased translocation of MAMPs, the consequences may include:

• Activation of low grade inflammation
• Elevation of biomarkers such as LBP and sCD14
• Metabolic and immunological effects in peripheral tissues

Integrated Interpretation

The figure demonstrates that the immune system does not recognize microorganisms individually, but rather conserved structural patterns. These patterns are detected at three main levels:

1. Cell surface
2. Endosomal compartments
3. Cytoplasm

The combination of pattern type, receptor location, and adaptor pathway determines the biological outcome.

Under physiological conditions, this system sustains tolerance and immune calibration. Under dysbiosis or increased intestinal permeability, it may contribute to chronic low grade inflammation.

The central message of the figure is that disease is not determined simply by the presence of bacteria, but by the quality, intensity, and context of molecular signaling interpreted by pattern recognition receptors.

Intestinal barrier, metabolic endotoxemia and immunometabolism

The intestinal mucosa is the largest immunological interface of the organism. A substantial portion of immune system cells resides in the intestine and associated tissues. What is fascinating, and at the same time dangerous, is that this interface needs to fulfill two opposing missions: tolerate what is physiological and react to what is threatening.

Under physiological conditions, there is active tolerance to the commensal microbiota. This tolerance is sustained by fine regulation of PRRs and by networks of regulatory cytokines, including IL 10 and TGF beta. A classic work by Rakoff Nahoum and Medzhitov, in 2004, showed that recognition of commensal microflora by Toll type receptors is required for intestinal homeostasis, which reinforces that signaling of microbial patterns, in the right dose and context, is not a problem, it is part of the biological design of the host.

The problem emerges when dysbiosis, a diet rich in saturated fats, chronic stress, poor sleep, alcohol, or repeated antibiotic use alter intestinal ecology, reducing mucus, altering epithelial junctions and increasing permeability. This phenomenon allows greater passage of MAMPs, or complexes containing MAMPs, into the systemic circulation.

Cani in 2007 described the concept of metabolic endotoxemia by relating increased lipopolysaccharide and activation of the LPS CD14 axis with insulin resistance and weight gain. Although measuring LPS in plasma in humans is methodologically sensitive, the clinical field often uses proxies of LPS exposure and microbial translocation, such as LBP and sCD14, in addition to associated inflammatory markers. The usefulness of these markers is discussed in works on postprandial transporters and metabolic inflammation, and associative studies in humans show relationships between LBP, cardiovascular risk and mortality, reinforcing the translational relevance of the LPS axis.

From that point on, inflammation ceases to be only defense against pathogens and becomes part of energy metabolism. Adipose tissue macrophages, when recognizing pattern signals and responding to systemic mediators, can migrate toward a more pro inflammatory phenotype, producing TNF alpha and IL 6, interfering with insulin signaling and perpetuating an inflammatory metabolic cycle.

This integration between immunity and metabolism is not an academic detail. It helps explain why interventions that restore barrier integrity, improve dietary composition and modulate the microbiota can produce changes in inflammatory markers and, in some cases, in metabolic parameters.

MAMPs, gut brain axis and neuroinflammation

The gut brain interface has moved beyond hypothesis and has become an established field. Cryan and Dinan, in 2012, presented an influential synthesis discussing how the microbiota can communicate with the central nervous system through neural, endocrine and immune pathways. Later reviews, including syntheses by Cryan and collaborators in 2019, reinforce that this communication involves multiple mediators, including microbial components, metabolites and inflammatory pathways.

MAMPs enter this scenario through a pragmatic route: peripheral inflammation changes the brain. The intestinal mucosa is innervated and connected to the central nervous system by the vagus nerve, the hypothalamic pituitary adrenal axis, circulating cytokines, and trafficking immune cells. When MAMPs interact with PRRs in intestinal epithelial and immune cells, cytokines are produced that can reach systemic circulation or modulate neural circuits.

Lipopolysaccharide at high concentrations is a classic model of inflammatory challenge. In humans, controlled studies with endotoxin administration have shown increased cytokines and transient emotional and cognitive changes. Reichenberg in 2001 demonstrated increased anxiety and depressed mood after endotoxin in volunteers, along with elevation of inflammatory mediators. Eisenberger in 2010 explored effects of induced inflammation on reward circuits, with changes associated with anhedonia. These studies do not mean that depression is caused by endotoxin, but they support that systemic inflammation can modulate central symptoms in humans, offering plausibility for inflammatory subphenotypes.

Microglia, the main immune cell of the central nervous system, expresses pattern recognition receptors and responds to inflammatory stimuli. Erny in 2015 demonstrated that the microbiota influences microglial maturation and function. In germ free models, microglia can show altered phenotype and responsiveness, suggesting that physiological microbial signals participate in fine tuning neuroimmune balance.

In neurodegeneration, there is growing interest in the role of Toll type receptors, with reviews addressing the participation of TLR2 and TLR4 in diseases such as Parkinson and Alzheimer, including from the microglia perspective. Specific reviews discuss how TLR2 and TLR4 may be altered in Parkinson and possibly connected to early intestinal dysfunction.

The clinically useful point is that the gut brain axis may be modulable through strategies that reduce MAMP translocation, restore the barrier and recalibrate peripheral immune response, which is not a ready therapeutic promise, but a plausible translational roadmap.

Trained immunity, epigenetics and innate memory

Traditionally, immunological memory was attributed to adaptive immunity. However, in recent decades, the concept of trained immunity has gained strength by demonstrating that innate cells can also undergo durable functional reprogramming. Netea in 2016 described this phenomenon as a form of innate immune "memory", mediated by epigenetic and metabolic reprogramming.

Beta glucans, for example, can induce changes in monocytes and macrophages that impact future response. On the other hand, repeated exposure to lipopolysaccharide can induce endotoxin tolerance, with attenuated inflammatory response to subsequent stimuli. This balance between training and tolerance is one of the keys to understanding why the same type of signal, at different doses and frequencies, can generate opposite results.

Clinically, this epigenetic layer supports an idea that needs to be handled with care, but has enormous value: repeated, low intensity and well targeted interventions can re educate immune tone. It is not immunosuppression, it is recalibration.

Postbiotics, purified MAMPs and molecular engineering

The concept of postbiotics emerged as a response to the need for greater predictability and standardization. In 2021, an ISAPP consensus panel led by Salminen and collaborators defined a postbiotic as a preparation of inanimate microorganisms and or their components that confers a health benefit on the host. This definition, by itself, repositions the discussion. The focus shifts from viability as dogma to demonstrable function and compositional standardization.

Purified MAMPs, cell wall fractions, lipoproteins and other components can be employed in a controlled way, with less ecological variability than live organisms. This does not eliminate complexity, but shifts complexity to molecular characterization and to dose and delivery route design. In the translational field, there is an example that became very didactic for the modern debate: microorganisms that, even inactivated, can maintain metabolic and immunological effects. The discussion around Akkermansia muciniphila helped consolidate this reasoning. Depommier in 2019 conducted a human trial showing that the pasteurized form of Akkermansia can improve insulin sensitivity and reduce insulinemia, with favorable signals in metabolic parameters, suggesting that structural components and membrane proteins may be an important part of the mechanism. This type of evidence reinforces that function is not synonymous with colonization.

Molecular engineering also points to future possibilities, such as designing partial agonists of PRRs, for example TLR2 modulators with a more regulatory profile. The promise here is not to activate inflammation, it is to activate tolerance and balance, and this requires biomarkers and very clear safety criteria.

Nanotechnology and targeted delivery systems

The stability of microbial components can be affected by gastric pH, enzymes and oxidation. Microencapsulation and nanoencapsulation systems can protect structures until the desired site. In addition to protection, these systems allow modulation of exposure kinetics. In mucosal immunology, dose and time matter as much as the identity of the signal.

Targeted delivery to the ileum or colon can alter which cells have primary contact with the component, modifying the outcome. Abrupt release tends to favor inflammatory peaks. Gradual release tends to favor tolerance and modulated responses, when the component and the context allow.

From a translational point of view, this creates an operational link between MAMP biology and pharmaceuticotechnical design, a link often ignored when the debate is stuck on CFU and label.

Artificial intelligence, predictive modeling and precision medicine

The PRR signaling network is complex, with redundancies, synergies and feedback loops. Traditional linear models do not capture this dynamic well. Machine learning tools can integrate structure, transcriptome and cytokines to predict response, and this is particularly useful when considering human heterogeneity, with receptor polymorphisms and profound microbiota variation.

Precision medicine, in this scenario, ceases to be only human genomics and begins to include microbial genomics, component structure and host immune phenotype. The practical goal is to better stratify who responds, how they respond, and with what risk.

Clinical implications of MAMPs, from concept to bedside, with biomarkers

The clinical usefulness of MAMPs begins when we leave the question "which bacterium" and move to "which signal" and "which measurable outcome". In clinical practice and applied research, this means working with biomarkers, phenotypes and endpoints.

Direct measurement of plasma LPS in humans presents methodological limitations and analytical variability, which is why clinical studies often use indirect markers, such as LBP and sCD14, together with inflammatory panels. Works discussing postprandial transporters and translocation markers help justify the use of these biomarkers as part of the translational arsenal.

Inflammatory bowel disease, NOD2 as a mechanistic anchor point

The genetic association of NOD2 with Crohn's disease was described by Hugot in 2001, connecting susceptibility to altered recognition of bacterial components. On the mechanistic level, Girardin in 2003 showed that NOD2 recognizes muramyl dipeptide as the minimal motif of peptidoglycan, and Inohara in 2003 reinforced the functional relevance of this axis by showing failures of response to muramyl dipeptide in carriers of associated mutations.

From a clinical point of view, this suggests that part of intestinal inflammation can arise not only from the presence of specific microorganisms, but from distorted interpretation of physiological signals. In applied terms, this creates two translational lines. The first is to reduce excessive inflammatory signals, for example by minimizing pattern translocation during phases of fragile barrier. The second is to explore re education of the response, something more complex, and possibly dependent on subphenotypes, genetics and mucosal status.

Useful biomarkers in this scenario include fecal calprotectin, CRP, blood count, cytokines in panels, and permeability and translocation markers when the study design justifies. Real world clinical practice does not rely on a single marker, but on a coherent set.

Metabolic syndrome and type two diabetes, metabolic endotoxemia as an operational axis

Cani in 2007 provided an experimental basis for the concept of metabolic endotoxemia and the LPS CD14 axis. In humans, the evidence is more heterogeneous, but associations between LBP, cardiometabolic risk and inflammation are recurrent, and studies with interventions in microbiota, diet and microbial components point to the possibility of modulating low grade inflammation.

What changes with the MAMP lens is the choice of endpoints. Instead of looking only at weight, the design becomes more robust when

it measures HOMA IR, HbA1c, insulinemia, lipid profile, high sensitivity CRP, IL 6, and includes LBP and sCD14 when the hypothesis involves microbial translocation. This makes interpretation less subjective and more compatible with scientific requirements.

As a relevant translational example, Depommier in 2019 demonstrated in humans that supplementation with pasteurized Akkermansia muciniphila can improve insulin sensitivity and reduce insulinemia, reinforcing that inanimate components and membrane structures can mediate effects, which directly connects with the concept of postbiotics.

Neuroinflammation and neurodegenerative diseases, prudence and plausibility

In this theme, it is necessary to clearly distinguish experimental evidence from clinical evidence. Most mechanistic data derive from pre clinical models and integrative reviews, while in humans associations and plausible hypotheses still under validation predominate. Reviews on TLR2 and TLR4 in Parkinson highlight homeostasis dysfunction and possible signaling alterations.

In translational practice, the initial target is indirect, reducing peripheral inflammation, improving the barrier, and monitoring objective signals. Possible biomarkers include CRP, IL 6, TNF alpha, and translocation markers. Clinical endpoints depend on the disease, motor and non motor scales in Parkinson, for example, and evaluation of gastrointestinal symptoms as a relevant component.

Depression and affective symptoms induced by inflammation, direct human evidence of inflammatory challenge

The human endotoxin administration literature is particularly useful because it shows acute causality between inflammation and symptoms, albeit transient. Reichenberg in 2001 observed increased depressed mood and anxiety with cytokine elevation after endotoxin. Eisenberger in 2010 explored alterations in reward circuits, associated with anhedonia, during inflammatory challenge. This supports plausibility for inflammatory subphenotypes of depression and for the idea that reducing inflammatory burden can benefit a subset of patients, without promising a universal effect.

The translational point here is stratification. Not all depression is inflammatory. The precision path is to identify who has an inflammatory signature, and only then consider immune and microbial modulation interventions as adjuvants.

MAMPs and next generation probiotics, from counting to function, from CFU to signal

The traditional literature on probiotics remained, for many years, tied to viability and counting. This was historically important because the field needed minimum quality standards. This approach, although historically relevant, is insufficient to capture functional differences between strains and their molecular patterns. Next generation probiotics require that the central question be functional: which molecular pattern does this strain carry, how is it perceived by PRRs and what measurable outcome does it produce.

Two strains of the same species can induce different responses because they exhibit differences in cell wall architecture, lipoproteins, exopolysaccharides and other components. This variation alters receptor affinity and activation pattern, such as TLR2. There are studies that evaluate and discuss anti inflammatory signaling mechanisms via Toll type receptor pathways in probiotics, including with focus on mucosal tolerance and epithelial regeneration.

From an applied point of view, the next generation probiotic ceases to be a "product that carries bacteria" and becomes a tool for signal engineering. This changes study design, quality control and even the regulatory conversation, because the rationale shifts from only "viable" to "biologically predictable".

An essential point to maintain rigor is to separate three concepts that are often mixed: colonization, persistence and effect. An effect can occur without durable colonization, through repeated and transient exposure to patterns and components. This is not rhetoric, it is a hypothesis supported by examples in which inactivated microorganisms maintain effect, as discussed in the postbiotic field and illustrated by trials with pasteurized Akkermansia.

Translational applications and future strategies, with a clinical roadmap

Translational applications can be organized into five complementary strategies.

Strategy 1, reduce translocation and load of inflammatory MAMPs in states of compromised barrier

Potential indications: metabolic syndrome with low grade inflammation, dysbiosis with gastrointestinal symptoms and elevated inflammatory markers, inflammatory subphenotypes in psychiatric conditions.

Useful biomarkers: high sensitivity CRP, IL 6, TNF alpha, LBP, sCD14, metabolic profile, in addition to clinical measures.

Strategy 2, immune re education with modulatory components, not suppressors

Here enter partial agonists, cell wall components with a regulatory profile, and trained immunity or tolerance approaches, always with dose and safety control.

Biomarkers and endpoints should include not only cytokines, but also functional and clinical markers, to avoid the illusion of "laboratory improvement" without patient improvement.

Strategy 3, combine microbial patterns with microbial metabolites

Short chain fatty acids, such as butyrate, modulate epigenetics and specific receptors, and can be synergistic with structural components, but this combination requires careful design to avoid paradoxical responses.

Strategy 4, targeted delivery and controlled kinetics

At this point, nanotechnology becomes operationally relevant by allowing control of dose, site and exposure kinetics.

Strategy 5, personalized stratification

Receptor polymorphisms and microbiota heterogeneity require stratification. Real precision medicine begins when it defines who has a chance to respond.

What not to promise, to maintain scientific credibility and protect the project

In a field as seductive as microbiota, immunity and MAMPs, the greatest risk is not missing a mechanistic detail, it is turning plausibility into promise. The biology of microbial patterns is real and powerful, but it operates in layers, depends on context, and above all, depends on phenotype. In practical terms, this means that the same component can modulate inflammation in one individual and amplify it in another, depending on intestinal barrier, baseline inflammatory load, comorbidities, diet, sleep, medication use and even receptor polymorphisms such as TLR4 and NOD2. Therefore, the first thing that is not promised is a universal effect. Communication by MAMPs is a language, and languages change meaning depending on context, including when the receptor, the environment and the immunometabolic state of the host are different.

Nor is direct causality in complex diseases promised based only on microbiological association. Microbiota alterations and markers such as LBP and sCD14 can be associated with cardiometabolic risk, systemic inflammation and neuropsychiatric phenotypes, but association is not proof of cause. Mechanistic evidence is robust in experimental models, and endotoxin studies in humans show that inflammation can induce symptoms acutely, as reported by Reichenberg in 2001 and by Eisenberger in 2010, but this does not authorize stating that depression, Parkinson or obesity are caused by LPS or isolated MAMPs. What can be stated with rigor is biological plausibility, mechanistic coherence and, in some contexts, benefit in specific endpoints in humans when interventions are well designed, as illustrated by the discussion of postbiotics and the translational example of Depommier in 2019.

Another important point is not to promise that measuring plasma LPS will solve the diagnosis of metabolic endotoxemia. In humans, direct LPS measurement is methodologically sensitive and can vary according to technique and interferences. Therefore, in well conducted clinical research, LBP and sCD14 are usually

used as proxies, and even then need to be interpreted together with high sensitivity CRP, IL 6, metabolic profile and the clinical context of the patient. The common error is to sell a marker as an oracle. The correct approach is to position biomarkers as part of a panel and a testable hypothesis.

Nor is it promised that probiotics are interchangeable, or that higher dose will always be better. The next generation probiotic idea requires abandoning quantity as the main criterion and adopting a reasoning of function, signal and outcome. Different strains have different MAMP signatures, and the same receptor can generate different outcomes depending on dose, time and delivery site. Promising that any shelf probiotic will reproduce a sophisticated mechanistic rationale weakens the text and opens technical vulnerability.

Finally, it is not promised that MAMP modulation strategies replace established treatments. The clinically responsible positioning is to treat these approaches as complementary, adjuvant and subject to validation by clinical trials, with safety and defined endpoints. Interpretive prudence and explicit delimitation between mechanistic plausibility and clinical evidence strengthen scientific robustness and reduce regulatory and methodological vulnerabilities.

A new clinical frontier, from combat to dialogue

Twentieth century immunology prioritized identifying the enemy and eliminating it. This logic was necessary and saved millions. But the twenty first century is making it clear that a relevant part of the modern problem is not lack of defense, it is lack of calibration. MAMPs represent the calibration code.

They can trigger destructive inflammation, but they can also sustain tolerance and homeostasis, as the literature on PRR mediated intestinal homeostasis has already demonstrated. The promising clinical frontier is to learn to modulate signals, with biomarkers, with study design and with prudence.

Chronic modern inflammation, in many scenarios, seems less like an external enemy and more like a problem of internal communication. If so, then biotechnology based on MAMPs, next generation probiotics and postbiotics can be a way to restore the biological language we lost along the way.

Conclusion and Next Steps

The available literature supports that recognition of MAMPs by PRRs is a central component of immunological homeostasis, as demonstrated by fundamental studies by Janeway and Medzhitov and further deepened by Akira and collaborators. Robust experimental evidence associates chronic exposure to lipopolysaccharide with metabolic inflammation, as described by Cani in 2007, and studies in humans show that systemic inflammation can modulate behavior and neural circuits, as observed by Reichenberg in 2001 and Eisenberger in 2010. In addition, exploratory clinical data with inactivated microorganisms, as in the study by Depommier in 2019, indicate that structural components can mediate measurable metabolic effects.

However, there is still not enough evidence to state that isolated modulation of MAMPs is a definitive therapy for complex diseases. The field requires clinical trials with prior patient stratification, use of biomarkers such as high sensitivity CRP, IL 6, LBP and sCD14 when appropriate, and clear definition of primary and secondary clinical endpoints.

Translational next steps include controlled pilot studies that combine assessment of intestinal permeability, microbial translocation markers and baseline inflammatory phenotype, followed by intervention with well characterized components, with rigorous control of dose, formulation and safety.

The transition from empirical microbiology to rational engineering of immunological signals requires precision, prudence and reproducibility. The promise of the field is great, but its consolidation will depend on the ability to transform mechanistic plausibility into replicable clinical evidence.

References

Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299(6710):p. 1259 a 1260. PMID: 2513902.

Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:p. 197 a 216. PMID: 11861602.

Akira S, Takeda K. Toll like receptor signalling. Nat Rev Immunol. 2004;4(7):p. 499 a 511. PMID: 15229469.

Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):p. 805 a 820. PMID: 20303872.

Rakoff Nahoum S, Paglino J, Eslami Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by Toll like receptors is required for intestinal homeostasis. Cell. 2004;118(2):p. 229 a 241. PMID: 15260992.

Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):p. 1761 a 1772. PMID: 17456850.

Cryan JF, Dinan TG. Mind altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):p. 701 a 712. PMID: 22968153.

Cryan JF, O Riordan KJ, Cowan CSM, et al. The microbiota gut brain axis. Physiol Rev. 2019;99(4):p. 1877 a 2013. PMID: 31460832.

Erny D, de Angelis ALH, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):p. 965 a 977. PMID: 26030851.

Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5):p. 445 a 452. PMID: 11343523.

Eisenberger NI, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68(8):p. 748 a 754. PMID: 20719303.

Netea MG, Quintin J, van der Meer JWM. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. PMID: 27102489.

Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):p. 649 a 667. PMID: 33948025.

Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof of concept exploratory study. Nat Med. 2019;25(7):p. 1096 a 1103. PMID: 31263284.

Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):p. 599 a 603. PMID: 11385576.

Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through the recognition of muramyl dipeptide. J Biol Chem. 2003;278(11):p. 8869 a 8872. PMID: 12527755.

Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. J Biol Chem. 2003;278(8):p. 5509 a 5512. PMID: 12514169.

Gorecki AM, Preskey L, Bakeberg MC, et al. TLR2 and TLR4 in Parkinson's disease pathogenesis. J Neuroinflammation. 2021;18(1):p. 1 a 15. PMID: 34717646.

